Results 11 to 20 of about 169,700 (260)

Effects of Immunomodulatory Therapy on the Skin Barrier Function in Patients with Psoriasis Vulgaris [PDF]

Medicina
Background and Objectives: Psoriasis vulgaris features epidermal barrier dysfunction. Materials and Methods: Barrier function changes were prospectively evaluated over 12 weeks during TNF-α inhibition with adalimumab, along with concurrent changes in ...
Anete Mālkalne, Vanda Bondare-Ansberga, Ilona Hartmane, Ingmārs Mikažāns, Lelde Reinberga   +4 more
doaj   +2 more sources

Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis

International Journal of Infectious Diseases, 2015
Objectives: Thymosin alpha1 (Tα1) is considered a promising immunomodulatory drug. However, it is still unclear whether Tα1 should be recommended for the management of sepsis. Here we conducted a systematic review and meta-analysis to assess the efficacy
Congcong Li, Liyan Bo, Qingqing Liu, Faguang Jin   +3 more
doaj   +3 more sources

Immunomodulatory Therapy for Rasmussen Syndrome

Pediatric Neurology Briefs, 2013
Investigators from the National Epilepsy Center, Shizuoka, Gifu University, Tokyo Women’s Medical University, National Center of Neurology and Psychiatry, and Okayama University School of Medicine, Japan, examined seizure, cognitive, and motor outcomes ...
J Gordon Millichap
doaj   +4 more sources

Immunopathogenesis and immunomodulatory therapy for myocarditis. [PDF]

Sci China Life Sci, 2023
Myocarditis is an inflammatory cardiac disease characterized by the destruction of myocardial cells, infiltration of interstitial inflammatory cells, and fibrosis, and is becoming a major public health concern. The aetiology of myocarditis continues to broaden as new pathogens and drugs emerge.
He W, Zhou L, Xu K, Li H, Wang JJ, Chen C, Wang D.   +6 more
europepmc   +3 more sources

Development of Blueberry-Derived Extracellular Nanovesicles for Immunomodulatory Therapy [PDF]

Pharmaceutics, 2023
Cuong Viet Pham, Rocky Chowdhury, Satendra K Jaysawal   +2 more
exaly   +2 more sources

Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study

Medicina, 2021
Background and Objectives: The treatment of Myeloma after the second relapse is still challenging. The aim of the study was to investigate the outcomes of the POM-DEX regimen in real clinical practice.
Maria Livia Del Giudice, Alessandro Gozzetti, Elisabetta Antonioli, Enrico Orciuolo, Francesco Ghio, Sara Ciofini, Veronica Candi, Giulia Fontanelli, Irene Attucci, Giuseppe Formica, Monica Bocchia, Sara Galimberti, Mario Petrini, Gabriele Buda   +13 more
doaj   +1 more source

The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies

eJHaem, 2023
Pomalidomide‐dexamethasone (Pd) has been a standard care treatment for relapsed and refractory multiple myeloma since 2013. However, the outcomes of Pd after exposure to CD38 antibodies are not known.
Agoston Gyula Szabo, Jonathan Thorsen, Katrine Fladeland Iversen, Mette Bøegh Levring, Carsten Helleberg, Emil Hermansen, Søren Thorgaard Bønløkke, Katrine Nielsen, Elena Manuela Teodorescu, Eva Kurt, Casper Nørgaard Strandholdt, Annette Juul Vangsted   +11 more
doaj   +1 more source

In dogs with atopic skin disease, is lokivetmab more effective than oclacitinib in reducing the score of a recognised scoring system?

Veterinary Evidence, 2022
PICO question In dogs with atopic skin disease, is lokivetmab more effective than oclacitinib in reducing the Canine Atopic Dermatitis Lesion Index score (or some other recognised scoring system)?
Bonnie Yuan Tone Cheung
doaj   +1 more source

Treatment Approaches for Atypical CIDP

Frontiers in Neurology, 2021
The variants of chronic inflammatory demyelinating polyneuropathy (CIDP) differ not just in their clinical, pathological and electrophysiological characteristics, but often in their indifferent response to conventional immunosuppressive agents which are ...
Deepak Menon, Hans Dieter Katzberg, Vera Bril   +2 more
doaj   +1 more source

Immunomodulatory therapies for COVID-19

Frontiers in Medicine, 2022
PurposeAs COVID-19 disease progresses, the host inflammatory response contributes to hypoxemia and severe and critical illness. In these latter stages of disease, patients may benefit from immunomodulatory therapies to control the aberrant host inflammatory response. In this review, we provide an overview of these therapies and provide summaries of the
Poonam Mathur, Shyamasundaran Kottilil
openaire   +3 more sources